After 6 weeks, hepatic steatosis improved in the TRF group, with decreased expression of aldehyde oxidase 1 (AOX1), a key enzyme involved in nicotinamide (NAM) catabolism, which mediates de novo lipogenesis and fatty acid uptake through the production of pro-steatotic metabolites. This evidence concerns the gene AOX1 and fatty liver disease.